Skye Bioscience Q1 net loss $11.1M; nimacimab combo shows >30% weight loss in preclinical

Skye Bioscience, Inc.

2025-Q1 EPS reported -$0.28

Net loss for Q1 2025 was $11.1M ($2.2M non-cash share-based comp) vs $5.0M in Q1 2024.
Cash and short-term investments total $59.2M; expected to fund operations through at least Q1 2027.
Preclinical DIO model: nimacimab + tirzepatide achieved >30% weight loss; nimacimab alone 23.5% comparable to monlunabant and tirzepatide alone.
In vitro data shows superior potency of peripherally restricted nimacimab vs small molecule monlunabant under pathological CB1 agonist levels.
Top-line data from Phase 2a CBeyond study of nimacimab expected late Q3/early Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.